Allergan
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Allergan sits in the top decile of US sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count).
Allergan: 314 sponsored US clinical trials, none currently recruiting.
Allergan sponsors 314 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 278 completed. 142 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ocular Hypertension, with 9 trials.
Top-decile sponsor footprint
Allergan ranks in the top decile of sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
278 of 313 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
314 total, page 2 of 7
Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites
NCT03376841
Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
NCT03091439
Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)
NCT03043287
Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing
NCT03166618
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
NCT02977507
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
NCT02965846
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
NCT03052764
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
NCT02859766
Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
NCT02961764
Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
NCT02959983
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
NCT02910713
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
NCT02815293
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
NCT02873221
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
NCT02848326
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02867709
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02828020
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
NCT02781311
Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia
NCT02848300
A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation
NCT02833077
A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia
NCT02780115
A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia
NCT02595528
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
NCT02676310
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT02636946
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
NCT02553772
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
NCT02634437
Perception of Facial Expression in Subjects With and Without Crow's Feet Lines
NCT02417077
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
NCT02557971
Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
NCT02554981
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
NCT02462928
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
NCT02462486
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
NCT02479139
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
NCT02420730
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
NCT02435914
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
NCT02411110
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
NCT02395042
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
NCT02357420
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
NCT02247804
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT02250651
A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief
NCT02455050
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
NCT02313454
A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease
NCT02280473
A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT02348476
A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
NCT02261493
A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides
NCT02261467
BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis
NCT02230956
Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
NCT02191579
Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
NCT02218034
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
NCT02181517
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
NCT02186119
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
NCT02197806
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 85 |
| Phase 3 | 91 |
| Phase 4 | 51 |
Therapeutic Areas
How the Allergan archive is shaped
314 indexed studies, none listed as recruiting (0% open); 278 completed (89%).
Phase mix: 142 late (III/IV) vs 114 early (I/II) (balanced across stages).
Top condition: Ocular Hypertension (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Allergan: archived-pipeline peers nationwide
Peers matched on 314 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Allergan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 314 archived trials
- University of Arkansas · 318 trials · 12% recruiting
- Rush University Medical Center · 320 trials · 17% recruiting
- Celgene · 308 trials · 4% recruiting
- Jonsson Comprehensive Cancer Center · 321 trials · 19% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Allergan page
314 registered trials is a research-attention snapshot, not an endorsement of Allergan or any single study.
- None of Allergan's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Ocular Hypertension is the condition Allergan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ocular Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Allergan pipeline card: 314 registered trials from official public datasets.Report a data error.